- Trial phase
- Phase 1/2 (first-in-human completed); Phase 3 ongoing
- Time to market
- Still in early-stage clinical development. Phase 1 results were just reported in November 2026, and Phase 3 trials are ongoing. If successful, potential approval is likely several years away (2029 or later).
- Why 2/10
- No hard dated catalyst is scheduled in the next ~12 months. Phase 1 results were just reported (November 8, 2026). Phase 3 trials are ongoing but no data readout date has been announced. As a JNJ asset, pasritamig is a tiny fraction of a ~$400B diversified healthcare company, so even a pivotal readout would have negligible impact on JNJ shares.
Pasritamig's Phase 1 results were reported on November 8, 2026, showing a 73% PSA response rate. The next catalyst is the ongoing Phase 3 trial (pasritamig + docetaxel vs docetaxel alone in mCRPC), but no specific data readout date has been announced. For JNJ, this is a very early-stage asset in a massive pipeline, so even positive Phase 3 data would have a negligible impact on JNJ's share price.
Price Chart
Executive Summary
Pasritamig (JNJ-78278343) is an investigational bispecific T-cell-engaging antibody being developed by Johnson & Johnson (JNJ) for metastatic castration-resistant prostate cancer (mCRPC). It targets KLK2, a protein found on prostate cancer cells, and directs the patient's T-cells to attack those cells. On November 8, 2026, J&J reported Phase 1 results showing a 73% PSA response rate (11 of 15 patients at the recommended regimen) for the combination of pasritamig and JNJ-9401 (a second bispecific targeting PSMA). The drug is advancing to Phase 3 testing. The filing hint linking pasritamig to Zymeworks (ZYME) is incorrect; pasritamig is wholly owned and developed by Johnson & Johnson, with no connection to Zymeworks.
How It Works
Pasritamig is a bispecific T-cell-engaging antibody, a type of immunotherapy. It works by binding to two targets simultaneously: one end grabs onto a protein called KLK2 (human kallikrein 2) found on prostate cancer cells, and the other end grabs onto CD3 receptors on the patient's own T-cells (immune cells). This forces the T-cells to get close to and kill the prostate cancer cells. It is being tested alone and in combination with JNJ-9401 (which targets a different prostate cancer protein called PSMA) to give a complementary immune signal.
Trial Status
Phase 1 first-in-human results for pasritamig + JNJ-9401 combination were reported on November 8, 2026, showing a 73% PSA response rate at the recommended Phase 2 regimen. A Phase 3 randomized open-label study of pasritamig + docetaxel vs docetaxel alone in mCRPC is ongoing (ASCO 2026 abstract). A Phase 1b/2 combination trial with GI Innovation's GI-102 is also underway.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 data readout for pasritamig + docetaxel vs docetaxel in mCRPC (no date announced)
- Phase 1b/2 combination data with GI-102 (GI Innovation collaboration)
- Additional Phase 1 monotherapy and combination data updates
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Zymeworks Inc. PRESS-RELEASE ZYME ·Originating report